Iron Isomaltoside in Treating Anaemia

 

Anemia is a condition in which the patient lacks enough healthy red blood cells to carry adequate oxygen to the body's tissues. Having anemia can make a person feel tired and weak. Iron deficiency anemia in short IDA is a problem related to multiple chronic disorders also includes chronic kidney disease (CKD). The main cause of anemia in patients with CKD are erythropoietin and iron deficiencies and also a decreased responsiveness to the actions of erythropoietin.

 

There are many forms of anemia, each with its own cause. Anemia can be temporary, and it can range from mild to severe. See your doctor if you suspect that you have anemia. It can be a warning sign of serious illness.

Treatments of anemia range from taking supplements to undergoing medical procedures. You might be able to prevent some types of anemia by eating a healthy, varied diet.

Women from third-world countries suffer the most due to blood loss during menstruation.

 

Treatment is required for anemia patients. In general iron, supplement is given to the patients. Treatment of oral iron is adequate for some patients but there are side effects like intolerance, inflammation, etc.

 

The International guidelines suggest IV iron preparations as the preferred option in the correction of Iron Deficiency Anemia in several of these circumstances especially when there is a high iron demand since it is more effective, tolerated by patients, and improves the quality of life to a greater extent than oral iron supplements.

 

(Iron Infusions first came about in the early twentieth century)

 

Iron Isomaltoside was introduced in Europe in 2010. It consists of iron and a carbohydrate moiety in which the iron is tightly bound in a matrix structure.

 

This enables a controlled and slow release of iron to iron-binding proteins that avoid potential toxicity from the release of labile iron.

 

The strongly bound iron within the Iron Isomaltoside formulation allows flexible dosing. You can use high dosing (single doses of 1–2 g) over a short time period without any harm. Compared to compounds in which iron is more loosely bound in the complex, the Iron Isomaltoside complex potentially leads to the generation of less oxidative stress and less immunological toxicity.

 

In the European Union, Iron Isomaltoside is administered with a maximum single dosage of 20 mg/kg actual body weight.

 

The dose flexibility and the possibility of providing full iron correction over a short time period in one visit make Iron Isomaltoside highly convenient for both the patients and healthcare professionals.

 

Several clinical trials, mainly short term, have been reported for Iron Isomaltoside where it has been shown to be well tolerated and to improve markers of IDA in patients receiving dialysis.

 

WBCIL is a leading manufacturer of Iron Isomaltoside and also exports to countries like Egypt, UAE, the US, etc. It is available in deep brown colored free-flowing powder. The packing size of Iron Isomaltoside is 20 kg in a sterile HDPE drum. The shelf life of Iron Isomaltoside is 36 months.